# Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

> **NCT00428090** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 862 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rosiglitazone

## Key facts

- **NCT ID:** NCT00428090
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-27
- **Primary completion:** 2008-09-01
- **Final completion:** 2008-09-05
- **Target enrollment:** 862 (ACTUAL)
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428090, "Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00428090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*